Company Name, Ticker, Suppliers, else..

• Gross Margin

• EBITDA Margin

• Operating Margin

• Pre-Tax Margin

• Effective Tax Rate

• Free Cash Flow Margin

• Cash Flow Margin

Valuation Comparisons

Management Effectiveness

Financial Strength

Dividend Comparisons

Gilead Sciences Inc (NASDAQ: GILD)

Sector • Healthcare Industry • Biotechnology & Pharmaceuticals

Industry • Biotechnology & Pharmaceuticals

Sector • Healthcare

Gilead Sciences Inc Profitability Comparisons

Select each Category to receive further Information

Select the Comparisons :

Profitability ▼

Select the Ratio:

None▼

Profitability ▼

None▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GILD Profitability Ratio	Company	Industry	Sector	S&P 500
Gross Profit Margin (Q2 MRQ)	79.76 %	71.11 %	65.43 %	46.05 %
Gross Margin (Q2 TTM)	79.59 %	79.56 %	66.39 %	46.3 %
Gross Profit Margin 5 Yr. Avg.	77.64 %	70.97 %	64.67 %	47.07 %
EBITDA Margin (Q2 MRQ)	-119.3 %	20.59 %	19.62 %	20.6 %
EBITDA Margin (Q2 TTM)	3.45 %	27.11 %	20.88 %	19.1 %
EBITDA Margin 5 Yr. Avg.	33.46 %	22.77 %	31.17 %	22.07 %
Operating Margin (Q2 MRQ)	-133.21 %	11.28 %	16.57 %	16.03 %
Operating Margin (Q2 TTM)	-8.2 %	16.53 %	17.92 %	16.33 %
Operating Margin 5 Yr. Avg.	26.21 %	6.03 %	14.41 %	17.09 %
Pre-Tax Profit Margin (Q2 MRQ)	-131.41 %	7.4 %	10.93 %	13.94 %
Pre-Tax Profit Margin (Q2 TTM)	-6.42 %	15.08 %	12.86 %	13.09 %
Pre-Tax Profit Margin 5 Yr. Avg.	22.52 %	9.88 %	10.45 %	12.49 %
Net Margin (Q2 MRQ)	-134.51 %	2.64 %	8.14 %	11.41 %
Net Margin (Q2 TTM)	-10.64 %	11.11 %	9.99 %	10.75 %
Net Margin 5 Yr. Avg.	18.14 %	6.58 %	6.23 %	9.95 %

Business Segment			Profit Margin

U S			-
Europe			-
Rest of World			-
Total product sales			-
Total product sales U S			-
Total product sales Europe			-
Total product sales Rest of World			-
Total HIV			-
Total HIV U S			-
Total HIV Europe			-
Total HIV Rest of World			-
Biktarvy			-
Biktarvy U S			-
Biktarvy Europe			-
Biktarvy Rest of World			-
Descovy			-
Descovy U S			-
Descovy Europe			-
Descovy Rest of World			-
Genvoya			-
Genvoya U S			-
Genvoya Europe			-
Genvoya Rest of World			-
Odefsey			-
Odefsey U S			-
Odefsey Europe			-
Odefsey Rest of World			-
Symtuza - Revenue share			-
Symtuza - Revenue share U S			-
Symtuza - Revenue share Europe			-
Symtuza - Revenue share Rest of World			-
Other HIV			-
Other HIV U S			-
Other HIV Europe			-
Other HIV Rest of World			-
Total Liver Disease			-
Total Liver Disease U S			-
Total Liver Disease Europe			-
Total Liver Disease Rest of World			-
Sofosbuvir Velpatasvir			-
Sofosbuvir Velpatasvir U S			-
Sofosbuvir Velpatasvir Europe			-
Sofosbuvir Velpatasvir Rest of World			-
Vemlidy			-
Vemlidy U S			-
Vemlidy Europe			-
Vemlidy Rest of World			-
Other Liver Disease			-
Other Liver Disease U S			-
Other Liver Disease Europe			-
Other Liver Disease Rest of World			-
Veklury			-
Veklury U S			-
Veklury Europe			-
Veklury Rest of World			-
Total Oncology			-
Total Oncology U S			-
Total Oncology Europe			-
Total Oncology Rest of World			-
Total Cell Therapy			-
Total Cell Therapy U S			-
Total Cell Therapy Europe			-
Total Cell Therapy Rest of World			-
Tecartus			-
Tecartus U S			-
Tecartus Europe			-
Tecartus Rest of World			-
Yescarta			-
Yescarta U S			-
Yescarta Europe			-
Yescarta Rest of World			-
Trodelvy			-
Trodelvy U S			-
Trodelvy Europe			-
Trodelvy Rest of World			-
Total Other			-
Total Other U S			-
Total Other Europe			-
Total Other Rest of World			-
AmBisome			-
AmBisome U S			-
AmBisome Europe			-
AmBisome Rest of World			-
Other			-
Other U S			-
Other Europe			-
Other Rest of World			-
Royalty contract and other revenues			-
Royalty contract and other revenues Europe			-
Royalty contract and other revenues Rest of World			-
Yeztugo			-
Yeztugo U S			-
Yeztugo Rest of World			-
Livdelzi			-
Livdelzi U S			-
Livdelzi Europe			-

Company's Cashflow Profitability & Other

Profitability Ratios	Company	Industry	Sector	S&P 500
Free Cash Flow Margin (Q2 MRQ)	44 %	1.35 %	0.21 %	1.39 %
Free Cash Flow Margin (Q2 TTM)	42.5 %	17.83 %	14.01 %	9.24 %
Free Cash Flow Margin 5 Yr. Avg.	-	17.1 %	15.38 %	14.52 %
Net Cash Flow Margin (Q2 MRQ)	0 %	0.42 %	-0.02 %	0.13 %
Net Cash Flow Margin (Q2 TTM)	8.16 %	4.99 %	0.08 %	1.81 %
Net Cash Flow Margin 5 Yr. Avg.	-	10.9 %	3.13 %	5.85 %
Effective Tax Rate (Q2 MRQ)	-2.36 %	63.94 %	25.41 %	18.83 %
Effective Tax Rate (Q2 TTM)	-65.7 %	26.44 %	22.81 %	19.33 %
Effective Tax Rate 5 Yr. Avg.	21.69 %	-399.76 %	20.39 %	19.86 %

Note
To view Detail Information & Trends click on Individual Category. Example: Y / Y Revenue Change (MRQ) or To see Industry, Sector or S&P 500 Performance, click on each Category respectivly, on the top of the Table. Example: Industry Sector S&P 500 For explanation of terms visit: Glossary

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.